Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.

In active psoriatic arthritis, certolizumab and secukinumab had some incremental cost-effectiveness ratios of £20,000-30,000 per QALY, depending on psoriasis severity and the previous treatments used.

http://ift.tt/2y1aVBI